Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to -$23.1 million.

  • Standard Biotools' Free Cash Flow rose 2335.68% to -$23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.4 million, marking a year-over-year increase of 3372.64%. This contributed to the annual value of -$151.8 million for FY2024, which is 22917.52% down from last year.
  • Per Standard Biotools' latest filing, its Free Cash Flow stood at -$23.1 million for Q3 2025, which was up 2335.68% from -$22.6 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Free Cash Flow ranged from a high of -$7.5 million in Q4 2021 and a low of -$63.3 million during Q1 2024
  • In the last 5 years, Standard Biotools' Free Cash Flow had a median value of -$19.8 million in 2021 and averaged -$22.6 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 6712.47% in 2023, then tumbled by 56621.38% in 2024.
  • Standard Biotools' Free Cash Flow (Quarter) stood at -$7.5 million in 2021, then tumbled by 167.06% to -$19.9 million in 2022, then rose by 29.08% to -$14.1 million in 2023, then dropped by 23.35% to -$17.4 million in 2024, then tumbled by 32.38% to -$23.1 million in 2025.
  • Its last three reported values are -$23.1 million in Q3 2025, -$22.6 million for Q2 2025, and -$35.3 million during Q1 2025.